Every 10-Q that SiNtx Technologies, Inc. (SINT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SINT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SINT filings page.
SINTX Technologies reported higher revenue but continued losses for the quarter ended June 30, 2026. Total revenue rose to $452 thousand for the quarter and $832 thousand for the first half of 2026, driven mainly by product revenue growth and initial sales of the SiNAPTIC Foot & Ankle Osteotomy Wedge System, along with OEM industrial products.
Despite this, the company remains loss-making, posting a net loss of $2.7 million for the quarter and $5.5 million year-to-date. Operating expenses increased to $3.2 million for the quarter as SINTX shifted overhead from R&D into general and administrative and expanded sales and marketing to support commercialization. Cash and cash equivalents were $3.6 million at June 30, 2026, after using $5.3 million in operating cash in the first half and raising capital through a $4.5 million private placement and $1.3 million of ATM sales.
Management explicitly states that substantial doubt exists about SINTX’s ability to continue as a going concern over the next 12 months, even after divesting non-core operations, subleasing the Armor facility, and accessing equity financing. The company’s strategy centers on leveraging its silicon nitride technology in higher-growth medical markets while maintaining its industrial ceramics business as a revenue base.
SINTX Technologies reported Q1 2026 revenue of $380,000 and a net loss of $2.8 million, as it continues investing in commercialization of its silicon nitride medical and industrial products.
Cash fell to $1.9 million with operating cash use of $2.5 million, and accumulated deficit reached $295 million. Management highlights new FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System and initial related revenue, plus growth in industrial applications.
However, the company states that substantial doubt exists about its ability to continue as a going concern over the next 12 months, despite cost actions, the TA&T divestiture, a sublease expected to save about $1.0 million, and remaining capacity of $5.7 million under its at-the-market equity program.
SINTX Technologies filed its Q3 2025 10‑Q, reporting total revenue of $208k (down 74% year over year) and a net loss of $3.539M. Gross profit was $93k, with operating expenses of $3.448M driven by R&D $1.264M and G&A $2.102M. Cash and cash equivalents were $6.250M as of September 30, 2025.
The company continued shifting away from low‑margin OEM work toward proprietary silicon nitride medical devices. It received FDA 510(k) clearance in October 2025 for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, with revenue expected to begin in the first half of 2026. Q3 also included an inducement in which holders exercised warrants for ~$3.8M in gross proceeds, creating a $6.7M deemed dividend.
SINTX strengthened liquidity with a $6.41M at‑the‑market facility established in October 2025 and expects ~$950k savings from subleasing the armor facility. Management states no significant uncertainty regarding its ability to continue as a going concern through at least November 12, 2026. Shares outstanding were 3,851,956 as of November 7, 2025.